Jan Pinkas
Chief Tech/Sci/R&D Officer at PYXIS ONCOLOGY, INC.
Jan Pinkas active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PYXIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 2022-04-11 | - |
| Corporate Officer/Principal | 2021-07-31 | 2022-04-11 |
Career history of Jan Pinkas
Former positions of Jan Pinkas
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Training of Jan Pinkas
| University of Massachusetts | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PYXIS ONCOLOGY, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Jan Pinkas
- Experience
